Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism

Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism - PREFER in VTE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004795

Enrollment

4500

Registered

2013-03-15

Start date

2013-01-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA - Venous Thromboembolism I82

Interventions

Group 1: - Patient characteristics - History of thromboembolic/bleeding events and diagnose of acute venous thromboembolism - Drug utiliation / use pattern of drugs for treatment of venous thromboembo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Established acute initial or recurrent VTE • In hospitals, surgical or non-surgical wards or specialised office-based centres • Written informed consent for participation in the registry (including telephone follow-ups) • Not simultaneously participating in a double blind interventional study

Exclusion criteria

Exclusion criteria: No explicit medical exclusion criteria are stated

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to assess the 12 month direct healthcare resource use and estimated costs following acute first time (initial) or recurrent venous thromboembolism. In addition, detailed insight on the characteristics and management of patients with acute venous thromboembolism (in particular deep vein thrombosis and/or pulmonary embolism) with focus on prevention of related events (e. g. bleeding or other complications, recurrence of deep vein tmbosis/pulmonary embolism, myocardial infarction, stroke, systemic embolic event, post thrombotic syndrome, percutaneous coronary intervention, coronary artery bypass graft, and death) will be collected.	—

Measure

Time frame

The primary objective of this study is to assess the 12 month direct healthcare resource use and estimated costs following acute first time (initial) or recurrent venous thromboembolism. In addition, detailed insight on the characteristics and management of patients with acute venous thromboembolism (in particular deep vein thrombosis and/or pulmonary embolism) with focus on prevention of related events (e. g. bleeding or other complications, recurrence of deep vein tmbosis/pulmonary embolism, myocardial infarction, stroke, systemic embolic event, post thrombotic syndrome, percutaneous coronary intervention, coronary artery bypass graft, and death) will be collected.

—

Secondary

Measure	Time frame
- To describe the treatment satisfaction (PACT Q2), health related quality of life (EQ 5D), and clinical outcomes following first time (initial) or recurrent venous thromboembolism. Timepoints: Baseline, 1, 3, 6 and 12 month(s) after baseline - To explore relationship between anticoagulants and duration of therapy and resource use, estimated costs, treatment satisfaction (PACT Q), and health related quality of life (EQ D5), and clinical outcomes. - To explore geographic variations in the management of patients with venous thromboembolism	—

Measure

Time frame

- To describe the treatment satisfaction (PACT Q2), health related quality of life (EQ 5D), and clinical outcomes following first time (initial) or recurrent venous thromboembolism. Timepoints: Baseline, 1, 3, 6 and 12 month(s) after baseline - To explore relationship between anticoagulants and duration of therapy and resource use, estimated costs, treatment satisfaction (PACT Q), and health related quality of life (EQ D5), and clinical outcomes. - To explore geographic variations in the management of patients with venous thromboembolism

—

Countries

Austria, France, Germany, Italy, Spain, Switzerland, United Kingdom

Contacts

Public ContactWolf-Peter Wolf

Daiichi Sankyo Europe GmbH

wolf-peter.wolf@daiichi-sankyo.eu+49-(0)89-70 08 308

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 4, 2026